MM-398
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Abstract Background Immunotherapy has increasingly become a staple in cancer treatment. However, substantial limitations in the…
A multicenter, open‐label, noncomparative, randomized phase II study (PEPCOL) was conducted to evaluate the efficacy and safety…
While progress in the treatment of advanced pancreatic cancer has accelerated in recent years, this malignancy continues to have…
Drug delivery system based on nanobiotechnology can improve the pharmacokinetics and therapeutic index of chemotherapeutic agents…
ABSTRACT Introduction: Systemic chemotherapy remains the standard of care for patients with advanced pancreatic ductal…
Purpose: To determine the pharmacokinetics and the antitumor activity in pediatric cancer models of MM-398, a nanoliposomal…
234 Background: MM-398 is a nanoliposomal encapsulation of irinotecan. OS in the ITT population was significantly longer with MM…
Background:PEP02, also known as MM-398, is a novel nanoliposomal irinotecan that has improved pharmacokinetics and tumour bio…
BACKGROUND
PEP02 is a novel highly stable liposomal nanocarrier formulation of irinotecan. This randomized phase II study…